26,884 Shares in Cerus Co. (NASDAQ:CERS) Purchased by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC bought a new stake in Cerus Co. (NASDAQ:CERS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 26,884 shares of the biotechnology company’s stock, valued at approximately $37,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rockport Wealth LLC purchased a new position in shares of Cerus during the fourth quarter valued at approximately $25,000. Merit Financial Group LLC purchased a new position in shares of Cerus during the 1st quarter worth $25,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Cerus during the fourth quarter worth $25,000. Cibc World Markets Corp purchased a new stake in shares of Cerus in the fourth quarter valued at $26,000. Finally, Virtu Financial LLC acquired a new position in Cerus in the fourth quarter valued at $33,000. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Cerus Trading Down 3.6%

CERS stock opened at $1.32 on Friday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The company has a market cap of $252.33 million, a price-to-earnings ratio of -12.00 and a beta of 1.55. The business has a fifty day simple moving average of $1.33 and a 200-day simple moving average of $1.54. Cerus Co. has a 52 week low of $1.12 and a 52 week high of $2.54.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $43.24 million during the quarter, compared to analyst estimates of $47.44 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. On average, equities research analysts expect that Cerus Co. will post -0.08 EPS for the current year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.